[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-aggregator-kiniksa-pharmaceuticals-nasdaq330195948d-7ee5-7040-9076-05cc0a9e59bc":3},{"id":4,"timestamp":5,"title":6,"content":7,"link":8,"preview":9,"tags":10,"predictedTags":10,"showTags":10,"source":11,"reactions":12,"selfReactions":13,"logo":14,"sourceId":15,"sourceUserId":16,"asset":17,"tagsCategories":18,"totalComments":19,"lang":20,"unique_views_count":21,"enrichStatus":17,"triageKind":16,"triageImportance":16,"expandEligible":16,"summarizeEligible":16,"eventEligible":16,"eventType":16,"eventAction":16},"kiniksa-pharmaceuticals-nasdaq330195948d-7ee5-7040-9076-05cc0a9e59bc","1741953456000","Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at Citigroup","Citigroup began coverage on Kiniksa Pharmaceuticals in a research note on Thursday. They set a \"buy\" rating and a $40.00 target price for the company.","https://www.marketbeat.com/instant-alerts/kiniksa-pharmaceuticals-nasdaqknsa-earns-buy-rating-from-analysts-at-citigroup-2025-03-13/","https://www.marketbeat.com/images/marketbeat-logo-1200-1200.jpg?v=1","[]","33",[],[],"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/news-feeds/sources/market-beat.png","Market Beat",null,"","[\"Other\"]","0","EN","1"]